Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for cetirizine / pseudoephedrine e, the scientific conclusions are as follows:

Based on cases retrieved from the literature with the mono components cetirizine and pseudoephedrine separately, a casual relationship between the combination cetirizine / pseudoephedrine and acute generalised exanthematous pustulosis (AGEP) was deemed likely. Although available cases of anaphylactic shock associated with cetirizine / pseudoephedrine are either confounded or poorly documented, a causal relationship between the combination cetirizine / pseudoephedrine and the event could never be excluded and it is also a listed event for cetirizine. Based on post-marketing cases reported cumulatively, a positive casual relationship was established between the combination cetirizine / pseudoephedrine and the following events: dyspnoea and eye disorders including accommodation disorder, blurred vision, mydriasis, eye pain, visual impairment and photophobia. Further, based on cumulative cases reported, a close temporal association between the combination cetirizine / pseudoephedrine and erectile dysfunction was established with positive dechallenge and rechallenge in patients without known risk factors. The PRAC therefore considered that section 4.8 of the Summary of product Characteristics of cetirizine / pseudoephedrine should include the adverse drug reactions AGEP, anaphylactic shock, dyspnoea, eye disorders and erectile dysfunction. The package leaflet is updated accordingly.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for cetirizine / pseudoephedrine the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing cetirizine / pseudoephedrine is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing cetirizine / pseudoephedrine are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.8 Undesirable effects

[The following adverse reaction should be added under the SOC Eye disorders with a frequency unknown]

Accommodation disorder, blurred vision, mydriasis, eye pain, visual impairment, photophobia

[The following adverse reaction should be added under the SOC Reproductive system and breast disorders with a frequency unknown]

Erectile dysfunction

[The following adverse reaction should be added under the SOC Respiratory, thoracic and mediastinal disorders with a frequency unknown]

Dyspnoea

[The following adverse reaction should be added under the SOC Skin and subcutaneous tissue disorders with a frequency not known]

Acute generalised exanthematous pustulosis

[The underlined adverse drug reaction wording should be added in the following text]

Immune System disorders: rare: hypersensitivity reactions **(including anaphylactic shock)**

[…]

Package Leaflet

- Section 4 Possible side effects

[The following adverse reactions should be added with a frequency not known]

- Severe skin reactions characterised by fever and numerous small, superficial pustules, arising within large areas of redness

- Difficulty breathing (dyspnoea)

- Accommodation disorder (eye disorder), blurred vision, abnormal pupil dilatation, eye pain, visual impairment, abnormal intolerance to visual perception of light

- Erectile dysfunction

[The underlined adverse drug reaction wording should be added in the following text]

Rare adverse reactions: *[…]* hypersensitivity reactions **(including anaphylactic shock)**

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	May 2017 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	1 July 2017
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	30 August 2017